wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q55264112-7AF1E8B5-FB15-4585-8074-C8BB3FAAAE51
Q55264112-7AF1E8B5-FB15-4585-8074-C8BB3FAAAE51
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55264112-7AF1E8B5-FB15-4585-8074-C8BB3FAAAE51
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
P2860
Q55264112-7AF1E8B5-FB15-4585-8074-C8BB3FAAAE51
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55264112-7AF1E8B5-FB15-4585-8074-C8BB3FAAAE51
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8b1c428378f34d7a8e32f21fe3f0bda47cc58439
P2860
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.